



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 10, 2025

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Earlier intimation dated July 23, 2025 & September 10, 2025

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Updates on proposed acquisition of shares in Adcock Ingram Holdings Limited

Hyderabad, India, October 10th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on proposed acquisition of shares in Adcock Ingram Holdings Limited

NATCO Pharma Limited had entered into a scheme of arrangement and made a firm intention announcement released on 23 July 2025 in relation to the proposed acquisition by NATCO Pharma South Africa Proprietary Limited of all of the issued ordinary shares in Adcock Ingram other than those not already held by NATCO, those currently owned by Bidvest and treasury shares of Adcock Ingram.

In that context, the Circular was released by Adcock Ingram to the shareholders of Adcock Ingram dated 9 September 2025 incorporating a notice convening the general meeting.

The General Meeting was held on 9 October 2025 at 1 PM South African Standard Time by way of in person / electronic participation. The Scheme Resolution required to approve the Scheme was tabled and put to vote.

The results of voting were as follows:

Resolution	For	Against	Number of Shares Voted	Shares voted disclosed as a % of total issued shares entitled to be voted in respect of the Scheme Resolution	Shares abstained disclosed as a% of the total issue shares entitled to be voted in respect of the Scheme Resolution
Scheme Resolution in accordance with sections 114(1)(c) and 115(2)(a) of the Companies Act of South Africa	98.66%	1.34%	36,825,684	73.16	0.01%

The Scheme Resolution was therefore passed by the requisite majority of votes exercised at the General Meeting. The quorum requirements were satisfied in accordance with the Companies Act and the Company's MOI.

The Scheme remains subject to the fulfilment or waiver of the outstanding conditions precedent set out in the Circular.

Once the Scheme becomes unconditional and the Takeover Regulation Panel of South Africa has issued a compliance certificate, the issued ordinary shares of Adcock Ingram will be delisted from the Main Board of the JSE Limited and the Adcock Ingram Shareholders recorded on the Adcock Ingram Securities Register on the Scheme Record Date will receive the Per Share Scheme Consideration of ZAR 75.00 per Adcock Ingram Share.

The final salient dates for the implementation of the Scheme and delisting of Adcock Ingram from the JSE will be announced in due course.

NATCO is being advised by Investec Bank Limited and Bowmans Gilfillan Inc.



NATCO Pharma Ltd

Natco House

Road No.2, Banjara Hills

Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE: NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's differentiated manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations

Email: ir@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences

Email: investors@natcopharma.co.in

Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: <https://www.linkedin.com/company/natcopharma>